Literature DB >> 30868755

Health-related quality of life in infants and children with interstitial lung disease.

Clara Lauby1, Pierre-Yves Boelle2, Rola Abou Taam1,3, Katia Bessaci1,4, Jacques Brouard1,5, Marie-Laure Dalphin1,6, Christophe Delacourt1,3, Céline Delestrain1,7, Antoine Deschildre1,8, Jean-Christophe Dubus1,9, Michaël Fayon1,10, Lisa Giovannini-Chami1,11, Véronique Houdouin1,12, Anne Houzel1,13, Christophe Marguet1,14, Isabelle Pin1,15, Philippe Reix1,16, Marie-Catherine Renoux1,17, Cyril Schweitzer1,18, Aurélie Tatopoulos1,18, Caroline Thumerelle1,8, Françoise Troussier1,19, Stéphanie Wanin1,12, Laurence Weiss1,20, Annick Clement1,21, Ralph Epaud1,7, Nadia Nathan1,21.   

Abstract

INTRODUCTION: Interstitial lung disease in children (chILD) is a highly heterogeneous group of rare and severe respiratory disorders. The disease by itself, the burden of the treatments (oxygen therapy, corticosteroid pulses, nutritional support) and recurrent hospitalizations may impair the quality of life (QoL) of these children. The aim of the study was to compare the health-related QoL (HR-QoL) in chILD compared to a healthy population and to find out the predictive factors of an altered QoL.
METHODS: Patients aged 1 month to 18 years with ILD of known or unknown etiology were prospectively included. Parents and children over 8 years old were asked to fill the PedsQL 4.0 Generic Core Scale ranging from 0 to 100 points.
RESULTS: A total of 78 children were recruited in 13 French pediatric centers. Total scores were 11.94 points (P = 0.0003) less for child self-report and 14.08 points ( P < 0.0001) less for parent proxy-report with respect to the healthy population. The clinical factors associated with a lower total score were: extrapulmonary expression of the disease, higher Fan severity score, long-term oxygen therapy, nutritional support, and a number of oral treatments.
CONCLUSION: Using a validated quality of life (QoL) scale, we showed that health-related-QoL is significantly impaired in chILD compared with a healthy population. Factors altering QoL score are easy to recognize and could help identify children at a heightened risk of low QoL.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  chILD; children; interstitial lung disease; quality of life; scale

Mesh:

Substances:

Year:  2019        PMID: 30868755     DOI: 10.1002/ppul.24308

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  5 in total

Review 1.  Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis.

Authors:  Robin R Deterding; Emily M DeBoer; Michal J Cidon; Terry E Robinson; David Warburton; Gail H Deutsch; Lisa R Young
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

Review 2.  Valuing the "Burden" and Impact of Rare Diseases: A Scoping Review.

Authors:  Julien Delaye; Pasquale Cacciatore; Anna Kole
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

Review 3.  Pulmonary Fibrosis in Children.

Authors:  Nadia Nathan; Chiara Sileo; Guillaume Thouvenin; Laura Berdah; Céline Delestrain; Effrosyne Manali; Spyros Papiris; Pierre-Louis Léger; Hubert Ducou le Pointe; Aurore Coulomb l'Hermine; Annick Clement
Journal:  J Clin Med       Date:  2019-08-26       Impact factor: 4.241

4.  Genomic testing for children with interstitial and diffuse lung disease (chILD): parent satisfaction, understanding and health-related quality of life.

Authors:  Lauren Kelada; Claire Wakefield; Nada Vidic; David S Armstrong; Bruce Bennetts; Kirsten Boggs; John Christodoulou; Joanne Harrison; Gladys Ho; Nitin Kapur; Suzanna Lindsey-Temple; Tim McDonald; David Mowat; André Schultz; Hiran Selvadurai; Andrew Tai; Adam Jaffe
Journal:  BMJ Open Respir Res       Date:  2022-02

5.  The role of exome sequencing in childhood interstitial or diffuse lung disease.

Authors:  Suzanna E L Temple; Gladys Ho; Bruce Bennetts; Kirsten Boggs; Nada Vidic; David Mowat; John Christodoulou; André Schultz; Thet Gayagay; Tony Roscioli; Ying Zhu; Sebastian Lunke; David Armstrong; Joanne Harrison; Nitin Kapur; Tim McDonald; Hiran Selvadurai; Andrew Tai; Zornitza Stark; Adam Jaffe
Journal:  Orphanet J Rare Dis       Date:  2022-09-09       Impact factor: 4.303

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.